Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Détails

ID Serval
serval:BIB_14C445174E2D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
Périodique
JAMA
Auteur(s)
Thompson M.A., Aberg J.A., Hoy J.F., Telenti A., Benson C., Cahn P., Eron J.J., Günthard H.F., Hammer S.M., Reiss P., Richman D.D., Rizzardini G., Thomas D.L., Jacobsen D.M., Volberding P.A.
ISSN
1538-3598 (Electronic)
ISSN-L
0098-7484
Statut éditorial
Publié
Date de publication
2012
Volume
308
Numéro
4
Pages
387-402
Langue
anglais
Notes
Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. Publication Status: ppublish. Author Contributions: Dr Thompson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Thompson, Aberg, Hoy, Telenti, Benson, Cahn, Eron, Günthard, Hammer, Reiss, Richman, Rizzardini, Thomas, Jacobsen, Volberding. Acquisition of data: Thompson, Hoy, Telenti, Benson, Richman, Volberding. Analysis and interpretation of data: Thompson, Aberg, Hoy, Benson, Cahn, Eron, Gu¨ nthard, Hammer, Reiss, Richman, Volberding. Drafting of the manuscript: Thompson, Aberg, Hoy, Telenti, Benson, Cahn, Richman, Thomas, Jacobsen, Volberding. Critical revision of the manuscript for important intellectual content: Thompson, Aberg, Hoy, Telenti, Benson, Cahn, Eron, Gu¨ nthard, Hammer, Reiss, Richman, Rizzardini, Thomas, Volberding. Obtained funding: Jacobsen. Administrative, technical, or material support: Jacobsen. Study supervision: Benson, Jacobsen, Volberding.
Résumé
CONTEXT: New trial data and drug regimens that have become available in the last 2 years warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected adults in resource-rich settings.
OBJECTIVE: To provide current recommendations for the treatment of adult HIV infection with ART and use of laboratory-monitoring tools. Guidelines include when to start therapy and with what drugs, monitoring for response and toxic effects, special considerations in therapy, and managing antiretroviral failure. DATA SOURCES, STUDY SELECTION, AND DATA EXTRACTION: Data that had been published or presented in abstract form at scientific conferences in the past 2 years were systematically searched and reviewed by an International Antiviral Society-USA panel. The panel reviewed available evidence and formed recommendations by full panel consensus.
DATA SYNTHESIS: Treatment is recommended for all adults with HIV infection; the strength of the recommendation and the quality of the evidence increase with decreasing CD4 cell count and the presence of certain concurrent conditions. Recommended initial regimens include 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase inhibitor (efavirenz), a ritonavir-boosted protease inhibitor (atazanavir or darunavir), or an integrase strand transfer inhibitor (raltegravir). Alternatives in each class are recommended for patients with or at risk of certain concurrent conditions. CD4 cell count and HIV-1 RNA level should be monitored, as should engagement in care, ART adherence, HIV drug resistance, and quality-of-care indicators. Reasons for regimen switching include virologic, immunologic, or clinical failure and drug toxicity or intolerance. Confirmed treatment failure should be addressed promptly and multiple factors considered.
CONCLUSION: New recommendations for HIV patient care include offering ART to all patients regardless of CD4 cell count, changes in therapeutic options, and modifications in the timing and choice of ART in the setting of opportunistic illnesses such as cryptococcal disease and tuberculosis.
Mots-clé
AIDS-Related Opportunistic Infections, Adult, Anti-Retroviral Agents/administration & dosage, Anti-Retroviral Agents/adverse effects, CD4 Lymphocyte Count, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections/complications, HIV Infections/drug therapy, Hepatitis B/complications, Hepatitis C/complications, Humans, Male, Medication Adherence, Pregnancy, Pregnancy Complications, Infectious/drug therapy, Quality of Health Care, RNA, Viral/blood, Societies, Medical, Treatment Failure
Pubmed
Web of science
Création de la notice
18/08/2012 10:06
Dernière modification de la notice
20/08/2019 12:43
Données d'usage